Richard S. Greenberg - 29 Nov 2021 Form 4 Insider Report for NEXIEN BIOPHARMA, INC. (NXEN)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
Richard S. Greenberg
Issuer symbol
NXEN
Transactions as of
29 Nov 2021
Net transactions value
$0
Form type
4
Filing time
29 Nov 2021, 11:23:19 UTC
Next filing
31 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NXEN Common Stock Award +500,000 +14% 4,185,192 29 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NXEN Class A Warrant 1,062,953 29 Nov 2021 common stock 1,062,953 $0.0403 Direct
holding NXEN Class B Warrant 1,062,953 29 Nov 2021 common stock 1,062,953 $0.0433 Direct
holding NXEN Class C Warrant 1,062,953 29 Nov 2021 common stock 1,062,953 $0.0452 Direct
holding NXEN Convertible note 40,000 29 Nov 2021 common stock 1,062,953 $0.0376 Direct
holding NXEN Options to purchase common stock (right to buy) 150,000 29 Nov 2021 common stock 150,000 $0.5400 Direct
holding NXEN Options to purchase common stock (right to buy) 100,000 29 Nov 2021 common stock 100,000 $0.6550 Direct
holding NXEN Options to purchase common stock (right to buy) 2,500,000 29 Nov 2021 common stock 2,500,000 $0.0800 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued in lieu of compensation for services.